Interpretive Practice Atlas

  • Daniel H.S. Silverman
  • Victoria Lau
  • Cheri Geist
  • Erin Siu

The interpretive practice atlas that follows has not been designed to serve as a typical atlas, in the sense of presenting a set of prototypical examples of a wide variety of clinical entities. Rather, it has been designed to provide actual clinical cases involving a series of brain positron emission tomography (PET) imaging sets that pose interpretive challenges that readers can realistically and repeatedly expect to face in most current clinical environments—where often the patient’s symptoms are mild or even questionable at the time of initial evaluation and the associated metabolic findings may be subtle.


Positron Emission Tomography Executive Functioning MMSE Score Frontotemporal Dementia Posterior Cingulate Cortex 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    1. Silverman DHS, Small GW, Chang CY,. Positron emission tomography in evaluation of dementia. JAMA 2001;286:2120–2127.PubMedCrossRefGoogle Scholar
  2. 2.
    2. Herholz K, Nordberg A, Salmon E,. Impairment of neocortical metabolism predicts progression in AD. Dement Geriatr Cogn Disord 1999;10:494–504.PubMedCrossRefGoogle Scholar
  3. 3.
    3. Silverman DHS, Truong CT, Kim SK,. Prognostic value of regional cerebral metabolism in patients undergoing dementia evaluation: comparison to a quantifying parameter of subsequent cognitive performance and to prognostic assessment without PET. Molec Genet Metab 2003;80:350–355.PubMedCrossRefGoogle Scholar
  4. 4.
    4. Hoffman JM, Welsh-Bohmer KA, Hanson M,. FDG PET imaging in patients with pathologically verified dementia. J Nucl Med 2000;41:1920–1928.PubMedGoogle Scholar
  5. 5.
    5. Silverman DHS. Brain 18F-FDG PET in the diagnosis of neurodegenerative dementias: comparison with perfusion SPECT and with clinical evaluations lacking nuclear imaging. J Nucl Med 2004;45:594–606.PubMedGoogle Scholar
  6. 6.
    6. Hoffman JM, Hanson MW, Welsh KA,. Interpretation variability of 18 FDG positron emission tomography studies in dementia. Invest Radiol 1996;31:316–322.PubMedCrossRefGoogle Scholar
  7. 7.
    7. Diehl-Schmid J, Grimmer T, Drzezga A,. Decline of cerebral glucose metabolism in frontotemporal dementia: a longitudinal 18F-FDG-PET-study. Neurobiol Aging 2007;28:42–50.PubMedCrossRefGoogle Scholar
  8. 8.
    8. Ishii K, Sakmoto S, Sasaki M,. Cerebral glucose metabolism in patients with frontotemporal dementia. J Nucl Med 1998;39:1875–1878.PubMedGoogle Scholar
  9. 9.
    9. Frank L, Matza LS, Hanlon J,. The patient experience of depression and remission: focus group results. J Nerv Ment Dis 2007;195:647–654.PubMedCrossRefGoogle Scholar
  10. 10.
    10. Copeland MP, Daly E, Hines V,. Psychiatric symptomatology and prodromal Alzheimer’s disease. Alz Dis Assoc Disord 2003;17:1–8.CrossRefGoogle Scholar
  11. 11.
    11. Minoshima S, Giordani B, Berent S,. Metabolic reduction in the posterior cingulate cortex in very early AD. Ann Neurol 2004;42:85–94.CrossRefGoogle Scholar
  12. 12.
    12. Weiner MF, Martin-Cook K, Foster BM,. Effects of donepezil on emotional/behavioral symptoms in Alzheimer’s disease patients. J Clin Psychiatry 2000;61:487–492.PubMedCrossRefGoogle Scholar
  13. 13.
    13. Silverman DHS, Cumming JL, Small GW,. assessment of the added clinical benefit of incorporating FDG-PET into the clinical evaluation of patients with cognitive impairment. Mol Imaging Biol 2002;4:283–293.PubMedCrossRefGoogle Scholar
  14. 14.
    14. Fago JP. Dementia: causes, evaluation, and management. Hosp Pract (Minneap) 2001;36:59–66, 69.Google Scholar
  15. 15.
    15. Whitehouse PJ, Friedland RP, Strauss ME. Neuropsychiatric aspects of degenerative dementias associated with motor dysfunction. The American Psychiatric Press Textbook of Neuropsychiatry, 2nd ed. Washington, DC: American Psychiatric Press, 1992, pp 585–604.Google Scholar
  16. 16.
    16. Silverman DHS, Gambhir SS, Huang HC,. Evaluating early dementia with and without assessment of regional cerebral metabolism by PET: a comparison of predicted costs and benefits. J Nucl Med 2002;43:253–266.PubMedGoogle Scholar
  17. 17.
    17. Doody RS, Geldmacher DS, Gordon B,. Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. Arch Neurol 2001;58:427–433.PubMedCrossRefGoogle Scholar
  18. 18.
    18. Rogers SL, Friedhoff LT. Long-term efficacy and safety of donepezil in the treatment of Alzheimer’s disease: an interim analysis of the results of a US multicentre open label extension study. Eur Neuropsychopharmacol 1998;8:67–75.PubMedCrossRefGoogle Scholar
  19. 19.
    19. Butters MA, Whyte EM, Nebes RD,. The nature and determinants of neuropsychological functioning in late-life depression. Arch Gen Psychiatry 2004;61:587–595.PubMedCrossRefGoogle Scholar
  20. 20.
    20. Chodosh J, Kado DM, Seeman TE,. Depressive symptoms as a predictor of cognitive decline: MacArthur studies of successful aging. Am J Geriatr Psychiatry 2007;15:406–415.PubMedCrossRefGoogle Scholar
  21. 21.
    21. Foster NL, Heidebrink JL, Clark CM,. FDG-PET improves accuracy in distinguishing frontotemporal dementia and Alzheimer’s disease. Brain 2007;130:2616–2635.PubMedCrossRefGoogle Scholar
  22. 22.
    22. Raskind MA, Peskind ER, Wessel T,. Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology 2000;54:2261–2268.PubMedGoogle Scholar
  23. 23.
    23. Corey-Bloom J, Anand R, Veach J. A randomized trial evaluating the efficacy and safety of ENA 713 rivastigmine tartrate, a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer’s disease: the ENA 713 B352 Study Group. Int J Geriatr Psychopharmacol 1998;1:55–65.Google Scholar
  24. 24.
    24. Coyle J, Kershaw P. Galantamine, a cholinesterase inhibitor that allosterically modulates nicotinic receptors: effects on the course of Alzheimer’s disease. Biol Psychiatry 2001;49:289–299.PubMedCrossRefGoogle Scholar
  25. 25.
    25. Morris JC, Cyrus PA, Orazem J,. Metrifonate benefits cognitive, behavioral, and global function in patients with Alzheimer’s disease. Neurology 1998;50:1222–1230.PubMedGoogle Scholar
  26. 26.
    26. Tariot PN, Solomon PR, Morris JC,. A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology 2000;54:2269–2276.PubMedGoogle Scholar
  27. 27.
    27. Imbimbo BP, Verdelli G, Martelli P,. Two-year treatment of Alzheimer’s disease with eptastigmine. The Eptastigmine Study Group. Dement Geriatr Cogn Disord 1999;10:139–147.PubMedCrossRefGoogle Scholar
  28. 28.
    28. Gregory A, Hayflick SJ. Neurodegeneration with brain iron accumulation. Folia Neuropathol 2005;43:286–296.PubMedGoogle Scholar
  29. 29.
    29. Clement F, Devos D, Moreau C. Neurodegeneration with brain iron accumulation: clinical, radiographic and genetic heterogeneity and corresponding therapeutic options. Acta Neurol Belg 2007;107:26–31.PubMedGoogle Scholar

Copyright information

© Springer Science + Business Media, LLC 2009

Authors and Affiliations

  • Daniel H.S. Silverman
    • 1
  • Victoria Lau
    • 2
  • Cheri Geist
    • 3
  • Erin Siu
    • 4
  1. 1.Division of Biological Imaging; Department of Molecular and Medical PharmacologyUCLA Alzheimer’s Disease Center Imaging Core, David Geffen School of Medicine, University of CaliforniaLos AngelesCA
  2. 2.Neuronuclear Imaging Section, Department of Molecular and Medical PharmacologyDavid Geffen School of Medicine, University of CaliforniaLos AngelesCA
  3. 3.Neuronuclear Imaging Section, Department of Molecular and Medical PharmacologyDavid Geffen School of Medicine, University of CaliforniaLos AngelesCA
  4. 4.Neuronuclear Imaging Section, Department of Molecular and Medical PharmacologyDavid Geffen School of Medicine, University of CaliforniaLos AngelesCA

Personalised recommendations